It is also common practice to perform HER2 testing in patients with advanced gastroesophageal cancer, colorectal cancer, lung cancer, ovarian cancer, endometrial cancer, bladder cancer, and head and neck cancer. The gene discussed is ERBB2; the disease is urinary bladder carcinoma.